A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

J. P. Dutcher, S. Creekmore, G. R. Weiss, K. Margolin, Avi Markowitz, M. Roper, D. Parkinson, N. Ciobanu, R. I. Fisher, D. H. Boldt, J. H. Doroshow, A. A. Rayner, M. Hawkins, M. Atkins

Research output: Contribution to journalArticle

216 Citations (Scopus)

Abstract

Thirty-six patients with metastatic melanoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy with high-dose interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Thirty-two patients who received all components of the therapy are evaluable for response, and all patients are evaluable for toxicity. Sites of disease included lung, liver, subcutaneous nodules, and intra-abdominal metastases. One complete response (CR) and five partial responses (PRs) resulted from treatment (19% response rate). The median response duration was 5 months, with the durable CR continuing at 31+ months and one durable PR continuing for 13 months. Sites of response included lung, liver, subcutaneous nodules, and lymph nodes. Response, response duration, or site of response did not correlate with the total dose of IL-2 administered, rebound lymphocytosis, or the number of LAK cells infused. Toxicity included hypotension, fluid retention with a 'capillary leak syndrome' in most patients, and transient multi-organ dysfunction that resolved promptly after the completion of therapy. Adverse cardiac events occurred in 16% of patients, with one myocardial infarction leading to a death. This study confirms the activity of the initial IL-2/LAK cell regimen in metastatic melanoma reported by Rosenberg et al, supporting the concept of adoptic immunotherapy as an important new treatment approach for this disease.

Original languageEnglish (US)
Pages (from-to)477-485
Number of pages9
JournalJournal of Clinical Oncology
Volume7
Issue number4
StatePublished - 1989
Externally publishedYes

Fingerprint

Lymphokine-Activated Killer Cells
Interleukin-2
Melanoma
Capillary Leak Syndrome
Adoptive Immunotherapy
Therapeutics
Lymphocytosis
Liver
Immunotherapy
Hypotension
Lung Diseases
Lymph Nodes
Myocardial Infarction
Neoplasm Metastasis
Lung

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dutcher, J. P., Creekmore, S., Weiss, G. R., Margolin, K., Markowitz, A., Roper, M., ... Atkins, M. (1989). A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. Journal of Clinical Oncology, 7(4), 477-485.

A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. / Dutcher, J. P.; Creekmore, S.; Weiss, G. R.; Margolin, K.; Markowitz, Avi; Roper, M.; Parkinson, D.; Ciobanu, N.; Fisher, R. I.; Boldt, D. H.; Doroshow, J. H.; Rayner, A. A.; Hawkins, M.; Atkins, M.

In: Journal of Clinical Oncology, Vol. 7, No. 4, 1989, p. 477-485.

Research output: Contribution to journalArticle

Dutcher, JP, Creekmore, S, Weiss, GR, Margolin, K, Markowitz, A, Roper, M, Parkinson, D, Ciobanu, N, Fisher, RI, Boldt, DH, Doroshow, JH, Rayner, AA, Hawkins, M & Atkins, M 1989, 'A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma', Journal of Clinical Oncology, vol. 7, no. 4, pp. 477-485.
Dutcher, J. P. ; Creekmore, S. ; Weiss, G. R. ; Margolin, K. ; Markowitz, Avi ; Roper, M. ; Parkinson, D. ; Ciobanu, N. ; Fisher, R. I. ; Boldt, D. H. ; Doroshow, J. H. ; Rayner, A. A. ; Hawkins, M. ; Atkins, M. / A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. In: Journal of Clinical Oncology. 1989 ; Vol. 7, No. 4. pp. 477-485.
@article{7619ea3b111b421f9d25835b36b6eb7b,
title = "A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma",
abstract = "Thirty-six patients with metastatic melanoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy with high-dose interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Thirty-two patients who received all components of the therapy are evaluable for response, and all patients are evaluable for toxicity. Sites of disease included lung, liver, subcutaneous nodules, and intra-abdominal metastases. One complete response (CR) and five partial responses (PRs) resulted from treatment (19{\%} response rate). The median response duration was 5 months, with the durable CR continuing at 31+ months and one durable PR continuing for 13 months. Sites of response included lung, liver, subcutaneous nodules, and lymph nodes. Response, response duration, or site of response did not correlate with the total dose of IL-2 administered, rebound lymphocytosis, or the number of LAK cells infused. Toxicity included hypotension, fluid retention with a 'capillary leak syndrome' in most patients, and transient multi-organ dysfunction that resolved promptly after the completion of therapy. Adverse cardiac events occurred in 16{\%} of patients, with one myocardial infarction leading to a death. This study confirms the activity of the initial IL-2/LAK cell regimen in metastatic melanoma reported by Rosenberg et al, supporting the concept of adoptic immunotherapy as an important new treatment approach for this disease.",
author = "Dutcher, {J. P.} and S. Creekmore and Weiss, {G. R.} and K. Margolin and Avi Markowitz and M. Roper and D. Parkinson and N. Ciobanu and Fisher, {R. I.} and Boldt, {D. H.} and Doroshow, {J. H.} and Rayner, {A. A.} and M. Hawkins and M. Atkins",
year = "1989",
language = "English (US)",
volume = "7",
pages = "477--485",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "4",

}

TY - JOUR

T1 - A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma

AU - Dutcher, J. P.

AU - Creekmore, S.

AU - Weiss, G. R.

AU - Margolin, K.

AU - Markowitz, Avi

AU - Roper, M.

AU - Parkinson, D.

AU - Ciobanu, N.

AU - Fisher, R. I.

AU - Boldt, D. H.

AU - Doroshow, J. H.

AU - Rayner, A. A.

AU - Hawkins, M.

AU - Atkins, M.

PY - 1989

Y1 - 1989

N2 - Thirty-six patients with metastatic melanoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy with high-dose interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Thirty-two patients who received all components of the therapy are evaluable for response, and all patients are evaluable for toxicity. Sites of disease included lung, liver, subcutaneous nodules, and intra-abdominal metastases. One complete response (CR) and five partial responses (PRs) resulted from treatment (19% response rate). The median response duration was 5 months, with the durable CR continuing at 31+ months and one durable PR continuing for 13 months. Sites of response included lung, liver, subcutaneous nodules, and lymph nodes. Response, response duration, or site of response did not correlate with the total dose of IL-2 administered, rebound lymphocytosis, or the number of LAK cells infused. Toxicity included hypotension, fluid retention with a 'capillary leak syndrome' in most patients, and transient multi-organ dysfunction that resolved promptly after the completion of therapy. Adverse cardiac events occurred in 16% of patients, with one myocardial infarction leading to a death. This study confirms the activity of the initial IL-2/LAK cell regimen in metastatic melanoma reported by Rosenberg et al, supporting the concept of adoptic immunotherapy as an important new treatment approach for this disease.

AB - Thirty-six patients with metastatic melanoma were entered into a study of the therapeutic efficacy of adoptive immunotherapy with high-dose interleukin-2 (IL-2) and lymphokine-activated killer (LAK) cells. Thirty-two patients who received all components of the therapy are evaluable for response, and all patients are evaluable for toxicity. Sites of disease included lung, liver, subcutaneous nodules, and intra-abdominal metastases. One complete response (CR) and five partial responses (PRs) resulted from treatment (19% response rate). The median response duration was 5 months, with the durable CR continuing at 31+ months and one durable PR continuing for 13 months. Sites of response included lung, liver, subcutaneous nodules, and lymph nodes. Response, response duration, or site of response did not correlate with the total dose of IL-2 administered, rebound lymphocytosis, or the number of LAK cells infused. Toxicity included hypotension, fluid retention with a 'capillary leak syndrome' in most patients, and transient multi-organ dysfunction that resolved promptly after the completion of therapy. Adverse cardiac events occurred in 16% of patients, with one myocardial infarction leading to a death. This study confirms the activity of the initial IL-2/LAK cell regimen in metastatic melanoma reported by Rosenberg et al, supporting the concept of adoptic immunotherapy as an important new treatment approach for this disease.

UR - http://www.scopus.com/inward/record.url?scp=0024544021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024544021&partnerID=8YFLogxK

M3 - Article

VL - 7

SP - 477

EP - 485

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 4

ER -